Axsome Therapeutics, Inc.
NASDAQ:AXSMBiotechnology
+$0.25 today
- Market cap
- $7.05B
- Beta
- 0.60
- P/E (TTM)
- -68.6
- EPS (TTM)
- -$3.68
Volume 0.74M
Average 0.72M
AXSM Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Axsome Therapeutics, Inc.NASDAQ: AXSM
Operating Income · Q2 FY2026 · quarter ended Jun 2026
Operating income remains negative
Q2 FY2026 operating income was -$49.65M, compared with -$36.71M a year earlier. Trailing-twelve-month operating income was -$188.54M.
Context
- Operating income amounted to 26.5% of revenue in FY2025, down 46.2 pp from a year earlier.
- Operating income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 16 analysts of -$121.16M (+28.4%) for the fiscal year ending Dec 2026, a slowdown from the +39.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$49.65M+21.6% QoQ
- Last fiscal yearDec 2025
- -$169.24M+39.7% YoY
- LTMJun 2026
- -$188.54M+17.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -35.2% | +31.6% | +66.8 pp |
| 1 year | +39.7% | +28.4% | -11.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (169.24M) USD
- Year-over-year change
- +39.7%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (169.24M) | +39.7% |
| FY2024 | 2024-12-31 | (280.56M) | -21.0% |
| FY2023 | 2023-12-31 | (231.83M) | -28.9% |
| FY2022 | 2022-12-31 | (179.8M) | -44.2% |
| FY2021 | 2021-12-31 | (124.71M) | — |
Operating Income vs competitors
How AXSM compares with its peers on the latest reported figures
- AXSM's LTM Jun 2026 operating income of -$188.54M is the 6th highest of the 11 companies compared; the peer median is -$172.65M.
- Its year-over-year change of +17.6% is the 5th highest of 11, against a peer median of -16.5%.
- Operating income amounts to 24.3% of revenue for AXSM, versus a peer median of 23.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $957.8M | +293.9% | — | 20.3% | |
| LTM Sep 2026 | $881.2M | +60.2% | +35.5% | 23.8% | |
| LTM Dec 2025 | -$44.6M | +19.1% | — | — | |
| LTM Jun 2026 | -$111.81M | -274.3% | — | 13.5% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$122.21M | -31.3% | — | 611.0% |
| LTM Jun 2026 | -$188.54M | +17.6% | — | 24.3% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$223.08M | +18.7% | — | — |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | -$254.15M | -68.1% | — | — |
| LTM Sep 2026 | -$406.72M | -38.8% | — | — | |
| LTM Sep 2026 | -$465.32M | -36.5% | — | — | |
| LTM Jun 2026 | -$542.7M | -1.7% | — | 15058.2% | |
| Peer median (excluding AXSM) | -$172.65M | -16.5% | +35.5% | 23.8% | |
Competitors are the stored peer set for AXSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 50.04M | 270.6M | 385.69M | 638.5M |
| Cost of Revenue | 0 | 5.2M | 26.07M | 33.3M | 47.48M |
| Gross Profit | 0 | 44.84M | 244.54M | 352.39M | 591.02M |
| Gross Margin | — | 89.6% | 90.4% | 91.4% | 92.6% |
| Research & Development | 58.06M | 57.95M | 97.94M | 187.08M | 183.28M |
| Selling, General & Admin | 66.65M | 159.25M | 323.12M | 411.36M | 570.6M |
| Operating Expenses | 124.71M | 224.64M | 476.36M | 632.95M | 760.25M |
| Depreciation & Amortization | 76K | 4.4M | 6.83M | 7.96M | 9.06M |
| EBITDA | (124.63M) | (175.4M) | (224.99M) | (272.6M) | (168.08M) |
| EBITDA Margin | — | -350.5% | -83.1% | -70.7% | -26.3% |
| Operating Income | (124.71M) | (179.8M) | (231.83M) | (280.56M) | (169.24M) |
| Operating Margin | — | -359.3% | -85.7% | -72.7% | -26.5% |
| Interest Income | 0 | 0 | 0 | 0 | 9.37M |
| Interest Expense | 5.7M | 7.34M | 6.45M | 6.57M | 6.56M |
| Other Income / Expenses | (5.7M) | (7.34M) | (6.45M) | (6.57M) | (14.47M) |
| Income Before Tax | (130.4M) | (187.13M) | (238.28M) | (287.13M) | (183.7M) |
| Pre-Tax Margin | — | -374.0% | -88.1% | -74.4% | -28.8% |
| Income Tax Expense | 0 | 0 | 960K | 85K | (530K) |
| Net Income | (130.4M) | (187.13M) | (239.24M) | (287.22M) | (183.17M) |
| Net Margin | — | -374.0% | -88.4% | -74.5% | -28.7% |
| EPS (Basic) | (3.47) | (4.60) | (5.27) | (5.99) | (3.68) |
| EPS (Diluted) | (3.47) | (4.60) | (5.27) | (5.99) | (3.68) |
| Weighted Avg Shares | 37.62M | 40.66M | 45.43M | 47.91M | 49.75M |
| Weighted Avg Shares (Diluted) | 37.62M | 40.66M | 45.43M | 47.91M | 49.75M |
Axsome Therapeutics, Inc.
NASDAQ:AXSM
Intrinsic Alpha fair value
Locked
Current Price
$134.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.